Clinical characteristics of COVID-19 patients with HIV coinfection in Wuhan, China.

Expert Rev Respir Med

Department of Infectious Diseases, Zhongnan Hospital, Wuhan University, Wuhan, China.

Published: March 2021

Background: Information about the impact of HIV coinfection on clinical characteristics of COVID-19 patients remains limited.

Methods: Maximum body temperatures, fever duration, chest CT and viral shedding, lymphocyte counts, and titer of SARS-CoV-2 antibody were compared between COVID-19 patients with and without HIV infection in Zhongnan Hospital of Wuhan University from January 20th to February 14th, 2020.

Results: Compared with 53 COVID-19 patients without HIV infection, the patients with SARS-CoV-2 and HIV coinfection had higher maximum body temperatures (38.7°C vs 37.6°C, = 0.044), longer duration of fever (8.7 ± 4.5 vs 4.2 ± 2.1 days, = 0.038), longer time to have improvement of chest CT images (22 vs 15 days from the onset of illness, = 0.011), lower level of SARS-CoV-2 IgG (5.11 ± 32.33 vs 37.45 ± 15.48 AU/ml, = 0.042). However, no statistically significant difference of duration of SARS-CoV-2 shedding in the two groups was found (12.3 ± 2.6 vs 13.4 ± 2.4 days, , = 0.813).

Conclusion: Lower level of CD4 T lymphocyte counts caused by HIV infection itself might be one of reasons for relatively weak ability to produce SARS-CoV-2 specific antibodies. The effects of anti-HIV drugs in prevention and treatment of COVID-19 appears to be limited.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605649PMC
http://dx.doi.org/10.1080/17476348.2021.1836965DOI Listing

Publication Analysis

Top Keywords

covid-19 patients
16
patients hiv
12
hiv coinfection
12
hiv infection
12
clinical characteristics
8
characteristics covid-19
8
maximum body
8
body temperatures
8
lymphocyte counts
8
compared covid-19
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!